Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium | ||||||||||||
By: GlobeNewswire - 27 Mar 2024 | Back to overview list |
|||||||||||
CORAL GABLES, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, CEO of Catalyst, along with other members of Catalyst’s management team, will participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium taking place virtually on April 2-3, 2024.
The presentation webcast will be available on the Investors section of the Company's website, and a replay will be accessible for at least 14 days. About Catalyst Pharmaceuticals For more information about Catalyst Pharmaceuticals, Inc., please visit the Company's website at?www.catalystpharma.com. For Full Prescribing and Safety Information for FIRDAPSE®, please visit www.firdapse.com. For Full Prescribing Information, including Boxed WARNING for FYCOMPA®, please visit www.fycompa.com. For Full Prescribing Information for AGAMREE®, please visit www.agamree.com. Forward-Looking Statements Source: Catalyst Pharmaceuticals, Inc. CONTACT: Investor Relations Contact: Mary Coleman, Catalyst Pharmaceuticals, Inc. (305) 420-3200 mcoleman@catalystpharma.com Media Contact: David Schull, Russo Partners (858) 717-2310 david.schull@russopartnersllc.com |
||||||||||||
|
||||||||||||
Copyright 2024 GlobeNewswire | Back to overview list |